Trihexyphenidyl HCl

Trihexyphenidyl HCl
Product Description

Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes trihexyphenidyl HCl. It belongs to anticholinergic / antiparkinsonian category. Bulk physical form: pellets. Final dosage form: caps. Contact us for more information.

Read more Show less

Osmopharm S.A.

  • CH
  • 2015
    On CPHI since
View company profile
Specifications
  • Details
    Dosage: 2 mg, 5 mg.
More specifications Fewer specifications

Osmopharm S.A.

  • CH
  • 2015
    On CPHI since
View company profile

More Products from Osmopharm S.A. (99)

  • Pyridoxine HCI

    Product Pyridoxine HCI

    Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes pyridoxine HCI. It belongs to vit. B6 deficiency category. Bulk physical form: pellets. Final dosage form: caps. Contact us for more information.
  • Salbutamol Sulphate

    Product Salbutamol Sulphate

    Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes salbutamol sulphate. It belongs to bronchodilator category. Bulk physical form: pellets, resinates. Final dosage form: caps/tabs. Contact us for more information.
  • Simvastatine

    Product Simvastatine

    Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes simvastatine. It belongs to hyperlipidemia / hyperchole category. Bulk physical form: pellets. Final dosage form: caps. Contact us for more information.
  • Theophylline

    Product Theophylline

    Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes theophylline. It belongs to bronchodilator category. Bulk physical form: pellets. Final dosage form: caps. Contact us for more information.
  • Tizanidine HCI

    Product Tizanidine HCI

    Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes tizanidine HCI. It belongs to muscle relaxant category. Bulk physical form: pellets. Final dosage form: caps. Contact us for more information.
  • Trifluoperazine HCI

    Product Trifluoperazine HCI

    Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes trifluoperazine HCI. It belongs to antipsychotic category. Bulk physical form: pellets. Final dosage form: caps. Contact us for more information.
  • Trimetazidine

    Product Trimetazidine

    Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes trimetazidine. It belongs to antianginal category. Bulk physical form: powder. Final dosage form: caps/tabs. Contact us for more information.
  • Acetazolamide

    Product Acetazolamide

    Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes acetazolamide. It belongs to diuretic category. Bulk physical form: Pellets. Final dosage form: caps. Contact us for more information.
  • Allopurinol

    Product Allopurinol

    Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes allopurinol. It belongs to antiurolytic category. Bulk physical form: Pellets. Final dosage form: caps. Contact us for more information.
  • Alprazolam

    Product Alprazolam

    Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes alprazolam. It belongs to anxiolytic category. Bulk physical form: Pellets. Final dosage form: caps. Contact us for more information.
  • Ambroxol HCI

    Product Ambroxol HCI

    Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes ambroxol HCI. It belongs to expectorant category. Bulk physical form: pellets, resinates. Final dosage form: caps/tabs. Contact us for more information.
  • Ambroxol HCI + Doxycicline Hyclate

    Product Ambroxol HCI + Doxycicline Hyclate

    Osmopharm S.A. studies, develops and produces modified release forms under contract manufacturing which includes ambroxol HCI + doxycicline hyclate. It is a pharmaceutical association. Bulk physical form: pellets. Final dosage form: caps. Contact us for more information.
show all 99 other products